0.06
+0.00465(+8.38%)
Currency In USD
| Previous Close | 0.06 |
| Open | 0.06 |
| Day High | 0.06 |
| Day Low | 0.06 |
| 52-Week High | 44.5 |
| 52-Week Low | 0.03 |
| Volume | 6 |
| Average Volume | 188,019 |
| Market Cap | 698,025 |
| PE | 0 |
| EPS | -45.44 |
| Moving Average 50 Days | 0.06 |
| Moving Average 200 Days | 6.58 |
| Change | 0 |
If you invested $1000 in Hepion Pharmaceuticals, Inc. (HEPA) 10 years ago, it would be worth $0 as of September 16, 2025 at a share price of $0.06. Whereas If you bought $1000 worth of Hepion Pharmaceuticals, Inc. (HEPA) shares 5 years ago, it would be worth $0.02 as of September 16, 2025 at a share price of $0.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
GlobeNewswire Inc.
Jun 25, 2025 12:30 PM GMT
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influ
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
GlobeNewswire Inc.
Jun 16, 2025 12:30 PM GMT
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influen
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire Inc.
May 12, 2025 8:30 PM GMT
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HC